The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.

The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.

The present disclosure provides a method of mitigating amyloid-related imaging abnormalities in a subject receiving an antibody therapy, such as a monoclonal antibody, for the treatment of Alzheimer's disease by administering an effective amount of an Angiotensin-(1-7) receptor agonist to the subject.

The present invention provides an angiotensin-(1-9) analog, particularly an angiotensin-(1-9) peptide synthesized from D-amino acids. This invention further involves the inversion of the original sequence of angiotensin-(1-9). This analog possesses an increased stability and maintains the biological activity of angiotensin-(1-9). Another embodiment of this invention comprises pharmaceutical compositions containing said analog and their use in the treatment of cardiovascular diseases, tissue remodeling in kidney, brain, and also the induction of cardioprotection.

The present disclosure provides an extended-release gel formulation containing a biocompatible polymer and an angiotensin-(1-7) oligopeptide or a variant thereof. Also provided are methods of treating subjects with vascular dementia, e.g., using the formulations disclosed herein or compositions containing the same, a subject can be administered the extended-release gel formulation to treat the vascular dementia.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and pain.

The present disclosure provides an extended-release gel formulation containing a biocompatible polymer and an angiotensin-(1-7) oligopeptide or a variant thereof. Also provided are methods of treating subjects with vascular dementia, e.g., using the formulations disclosed herein or compositions containing the same, a subject can be administered the extended-release gel formulation to treat the vascular dementia.

Methods for quality control and optimizing the formation and characterization of micelles, vesicles or other aggregates are described herein. Pharmaceutically relevant peptides may be modified to form glycopeptide surfactants which form micelles or other aggregates with another surfactant. Glycopeptide and glycolipid surfactants can aggregate to form particles that enhance drug delivery. The glycopeptide surfactants may be drugs or prodrugs which are delivered via the micelles or other aggregated structures.

The present invention concerns gamma-secretase inhibitors for use in the treatment of inherited epidermolysis bullosa and/or fibrosis associated to inherited epidermolysis bullosa, in particular for use in the treatment of recessive dystrophic epidermolysis bullosa and recessive dystrophic epidermolysis bullosa-associated fibrosis.

The present disclosure provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury.